{
    "title": "Novartis-Molecular Partners COVID drug could be approved in weeks",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10387451/Novartis-Molecular-Partners-COVID-drug-approved-weeks.html",
    "date": "2022-01-10",
    "keywords": [
        "novartis",
        "drug",
        "emergency",
        "molecular",
        "paul",
        "arnold",
        "authorization",
        "antibody",
        "ensovibep",
        "trial",
        "manufacturing",
        "payment",
        "approval",
        "volume",
        "drugmaker",
        "partner",
        "market",
        "monday",
        "marketing",
        "application",
        "chief",
        "executive",
        "patrick",
        "amstutz",
        "couple",
        "europe",
        "therapy",
        "target",
        "phase",
        "reduction",
        "load",
        "omicron",
        "option",
        "httpswwwreuterscombusinesshealthcarepharmaceuticalsnovartisinlicensescovid19treatmentensovibepmolecularpartners20220110",
        "responsibility",
        "development",
        "distribution",
        "return",
        "share",
        "spokesperson",
        "group",
        "food",
        "administration",
        "fda",
        "end",
        "use",
        "protocol",
        "advantage",
        "efficacy",
        "dosage",
        "infusion",
        "injection",
        "formulation",
        "franc",
        "cancer",
        "reporting",
        "writing",
        "mike",
        "silke",
        "koltrowitz",
        "lisa",
        "shumaker"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}